New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future

Bibliography

• Bosetti C, Bertuccio P, Chatenoud L, Childhood cancer mortality in Europe, 1970-2007. Eur J Cancer 2010;46(2):384-94
   PubMed Web of Science ®Google Scholar
• Magnani C, Pastore G, Coebergh JW, Trends in survival after childhood cancer in Europe, 1978-1997: report from the Automated Childhood Cancer Information System project (ACCIS). Eur J Cancer 2006;42(13):1981-2005
   PubMed Web of Science ®Google Scholar
• Ceschel S, Casotto V, Valsecchi MG, Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer 2006;47(5):560-6
   PubMed Web of Science ®Google Scholar
• Wagner S, Benesch M, Berthold F, Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer 2006;95(8):991-7
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
   PubMed Web of Science ®Google Scholar
• Rini BI. Sorafenib. Expert Opin Pharmacother 2006;7(4):453-61
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Rossler J, Geoerger B, Taylor M, Vassal G. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. Curr Cancer Drug Targets 2008;8(1):76-85
   PubMed Web of Science ®Google Scholar
• Rossler J, Taylor M, Geoerger B, Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008;44(12):1645-56
   PubMed Web of Science ®Google Scholar
• Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7(6):513-20
   PubMed Web of Science ®Google Scholar
• Asahara T, Takahashi T, Masuda H, VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18(14):3964-72
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):964-7
   PubMed Web of Science ®Google Scholar
• Nolan DJ, Ciarrocchi A, Mellick AS, Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007;21(12):1546-58
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S, Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7(11):1194-201
   PubMed Web of Science ®Google Scholar
• Peters BA, Diaz LA, Polyak K, Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005;11(3):261-2
   PubMed Web of Science ®Google Scholar
• Ruzinova MB, Schoer RA, Gerald W, Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003;4(4):277-89
   PubMed Web of Science ®Google Scholar
• Shaked Y, Ciarrocchi A, Franco M, Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313(5794):1785-7
   PubMed Web of Science ®Google Scholar
• Shaked Y, Henke E, Roodhart JM, Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14(3):263-73
   PubMed Web of Science ®Google Scholar
• Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007;67(15):7055-8
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79(2):185-8
   PubMed Web of Science ®Google Scholar
• Gao D, Nolan DJ, Mellick AS, Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319(5860):195-8
   PubMed Web of Science ®Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2(10):727-39
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5(6):423-35
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
   PubMed Web of Science ®Google Scholar
• Mancuso MR, Davis R, Norberg SM, Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116(10):2610-21
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-9
   PubMed Web of Science ®Google Scholar
• Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008;5(7):378-91
   PubMedGoogle Scholar
• Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94(12):883-93
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19(4):1207-25
   PubMed Web of Science ®Google Scholar
• Jubb AM, Hurwitz HI, Bai W, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24(2):217-27
   PubMed Web of Science ®Google Scholar
• Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6(8):626-35
   PubMed Web of Science ®Google Scholar
• Hanrahan E, Lin H, Kim E, Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28(2):193-201
   PubMed Web of Science ®Google Scholar
• Duda D, Ancukiewicz M, Jain R. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol 2010;28(2):183-5
   PubMed Web of Science ®Google Scholar
• Shaked Y, Bertolini F, Man S, Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7(1):101-11
   PubMed Web of Science ®Google Scholar
• Dignat-George F, Sabatier F, Blann A, Woywodt A. Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? J Clin Oncol 2007;25(5):e1-2, author reply e3-5
   PubMed Web of Science ®Google Scholar
• Mancuso P, Burlini A, Pruneri G, Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97(11):3658-61
   PubMed Web of Science ®Google Scholar
• Mancuso P, Colleoni M, Calleri A, Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108(2):452-9
   PubMed Web of Science ®Google Scholar
• Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6(11):835-45
   PubMedGoogle Scholar
• George F, Brisson C, Poncelet P, Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 1992;67(1):147-53
   PubMed Web of Science ®Google Scholar
• Mancuso P, Antoniotti P, Quarna J, Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009;15(1):267-73
   PubMed Web of Science ®Google Scholar
• Strijbos MH, Kraan J, den Bakker MA, Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom 2007;72(2):86-93
   PubMedGoogle Scholar
• Strijbos MH, Kraan J, Lamers CH, Quantification of circulating endothelial cells by flow cytometry. Clin Cancer Res 2009;15(10):3640, author reply -1
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Adamson PC, Reid JM, Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008;26(3):399-405
   PubMed Web of Science ®Google Scholar
• Jacques N, Vimond N, Conforti R, Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J Immunol Methods 2008;337(2):132-43
   PubMed Web of Science ®Google Scholar
• Taylor M, Rossler J, Geoerger B, High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 2009;15(14):4561-71
   PubMed Web of Science ®Google Scholar
• Shaked Y, Tang T, Woloszynek J, Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 2009;69(19):7524-8
   PubMed Web of Science ®Google Scholar
• Farace F, Massard C, Borghi E, Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 2007;18(8):1421-2
   PubMed Web of Science ®Google Scholar
• Roodhart JM, Langenberg MH, Vermaat JS, Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 2010;12(1):87-94
   PubMed Web of Science ®Google Scholar
• Dellapasqua S, Bertolini F, Bagnardi V, Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26(30):4899-905
   PubMed Web of Science ®Google Scholar
• Calleri A, Bono A, Bagnardi V, Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009;15(24):7652-7
   PubMed Web of Science ®Google Scholar
• Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14(2):405-14
   PubMed Web of Science ®Google Scholar
• Kieran MW. Anti-angiogenic therapy in pediatric neuro-oncology. J Neurooncol 2005;75(3):327-34
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4
   PubMed Web of Science ®Google Scholar
• Rowe DH, Huang J, Kayton ML, Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000;35(1):30-2, discussion 2-3
   PubMed Web of Science ®Google Scholar
• Kim ES, Serur A, Huang J, Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002;99(17):11399-404
   PubMed Web of Science ®Google Scholar
• McCrudden KW, Hopkins B, Frischer J, Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg 2003;38(3):308-14, discussion-14
   PubMed Web of Science ®Google Scholar
• Kim ES, Soffer SZ, Huang J, Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J Pediatr Surg 2002;37(3):518-22
   PubMed Web of Science ®Google Scholar
• Soffer SZ, Moore JT, Kim E, Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 2001;36(8):1177-81
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105(8):R15-24
   Web of Science ®Google Scholar
• Davidoff AM, Leary MA, Ng CY, Vanin EF. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001;36(1):30-6
   PubMed Web of Science ®Google Scholar
• Meco D, Riccardi A, Servidei T, Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett 2005;228(1-2):211-9
   PubMed Web of Science ®Google Scholar
• Geng L, Shinohara ET, Kim D, STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 2006;64(1):263-71
   PubMed Web of Science ®Google Scholar
• Beppu K, Jaboine J, Merchant MS, Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96(1):46-55
   PubMed Web of Science ®Google Scholar
• Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94(22):1673-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Smith KM, Chong AL, In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009;11(5):426-35
   PubMed Web of Science ®Google Scholar
• Lund EL, Olsen MW, Lipson KE, Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. Neoplasia 2003;5(2):155-60
   PubMed Web of Science ®Google Scholar
• Ma J, Li S, Reed K, Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 2003;305(3):833-9
   PubMed Web of Science ®Google Scholar
• Turner CD, Chi S, Marcus KJ, Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol 2007;82(1):95-101
   PubMed Web of Science ®Google Scholar
• Gilheeney SW, Lyden DC, Sgouros S, A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer 2007;49(3):261-5
   PubMed Web of Science ®Google Scholar
• Bond M, Bernstein ML, Pappo A, A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008;50(2):254-8
   PubMed Web of Science ®Google Scholar
• Kieran MW, Supko JG, Wallace D, Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 2009;52(2):169-76
   PubMed Web of Science ®Google Scholar
• Herrington B, Kieran MW. Small molecule inhibitors in children with malignant gliomas. Pediatr Blood Cancer 2009;53(3):312-7
   PubMed Web of Science ®Google Scholar
• Benesch M, Windelberg M, Sauseng W, Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008;19(4):807-13
   PubMed Web of Science ®Google Scholar
• Packer RJ, Jakacki R, Horn M, Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009;52(7):791-5
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Stewart CF, Kocak M, Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26(6):919-24
   PubMed Web of Science ®Google Scholar
• Maris JM, Courtright J, Houghton PJ, Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;51(1):42-8
   PubMed Web of Science ®Google Scholar
• Maris JM, Courtright J, Houghton PJ, Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(3):581-7
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60(7):1878-86
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res Treat 2007;39(4):150-9
   PubMedGoogle Scholar
• Samuel DP, Wen PY, Kieran MW. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs 2009;18(7):973-83
   PubMed Web of Science ®Google Scholar
• Stempak D, Seely D, Baruchel S. Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Invest 2006;24(4):432-43
   PubMed Web of Science ®Google Scholar
• Sterba J, Valik D, Mudry P, Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 2006;29(7):308-13
   PubMed Web of Science ®Google Scholar
• Stempak D, Gammon J, Halton J, A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28(11):720-8
   PubMed Web of Science ®Google Scholar
• Lopez-Aguilar E, Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children. Arch Med Res 2008;39(7):655-62
   PubMed Web of Science ®Google Scholar
• Kamba T, Tam BY, Hashizume H, VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290(2):H560-76
   PubMed Web of Science ®Google Scholar
• Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31
   PubMedGoogle Scholar
• Natori T, Sata M, Washida M, G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2002;297(4):1058-61
   PubMed Web of Science ®Google Scholar
• Wassberg E, Pahlman S, Westlin JE, Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997;41(3):327-33
   PubMed Web of Science ®Google Scholar
• Katzenstein HM, Rademaker AW, Senger C, Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 1999;5(12):4273-8
   PubMed Web of Science ®Google Scholar
• Kaicker S, McCrudden KW, Beck L, Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. Int J Oncol 2003;23(6):1651-5
   PubMed Web of Science ®Google Scholar
• Son MJ, Kim JS, Kim MH, Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. Int J Oncol 2006;28(1):53-9
   PubMed Web of Science ®Google Scholar
• Kuroiwa M, Takeuchi T, Lee JH, Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg 2003;38(10):1499-505
   PubMed Web of Science ®Google Scholar
• Joseph JM, Bouquet C, Opolon P, High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts. Cancer Gene Ther 2003;10(11):859-66
   PubMed Web of Science ®Google Scholar
• Yang Q, Tian Y, Liu S, Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007;67(4):1716-24
   PubMed Web of Science ®Google Scholar
• Vassal G, Geoerger B, Le Deley M, ITCC Phase II study of imatinib mesylate in children with solid tumors expressing imatinib-sensitive tyrosine kinase receptors. J Clin Oncol, ASCO Meeting Abstracts 2006;24:9003
   Google Scholar